Drug Profile
ABPI 127
Latest Information Update: 22 Dec 1999
Price :
$50
*
At a glance
- Originator Apollo BioPharmaceutics
- Class Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 22 Dec 1999 Discontinued-Preclinical for Stroke in USA (Unknown route)
- 07 Nov 1997 Preclinical development for Stroke in USA (Unknown route)